PEPEES Spolka Akcyjna

PEPEES Spolka Akcyjna

GGPW:PPS
0.73
PLN
-0.02
(-2.41%)
-0.17EPS
79.74MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.44
1.26
1.49
1.95
2.36
2.53
2.44
2.15
2.32
2.68
2.34
2.48
2.57
2.42
Basic EPS, GAAP
0.01
0.04
0.06
0.19
0.14
0.24
0.25
0.07
-0.03
0.11
0.04
-0.15
-0.11
-0.16
Free Cash Flow per Basic Share
0.09
-0.36
-0.09
0.02
0.06
- -
0.11
-0.09
0.15
0.18
-0.02
-0.03
-0.35
0.07
Dividend per Share
- -
- -
- -
- -
- -
- -
0.12
0.12
- -
- -
0.1
- -
- -
- -
Book Value per Share
1.12
1.09
1.15
1.35
1.49
1.74
1.88
1.83
1.81
1.93
1.89
1.76
1.66
1.63
Tangible Book Value per Share
1.11
1.09
1.14
1.28
1.45
1.7
1.84
1.79
1.79
1.91
1.87
1.74
1.64
1.61
Basic Weighted Avg Shares
83
92
95
95
95
95
95
95
95
95
95
95
95
95
Sales/Revenue/Turnover
120
116
142
186
224
240
232
204
221
255
222
236
244
231
Operating Margin (%)
2
4.47
6.09
12.19
11.68
12.9
15.42
5.23
-2.64
9.73
5.66
-3
-1.58
-4.21
Depreciation Expense
7
6
6
7
9
12
14
15
15
17
15
15
15
21
Net Income, GAAP
1
3
5
18
13
23
24
6
-2
11
4
-15
-11
-15
Effective Tax Rate (%)
50
24.68
25.21
21.07
29.27
23.03
23.83
26.47
- -
37.22
51.91
- -
- -
- -
Profit Margin (%)
0.55
2.9
3.74
9.48
5.96
9.62
10.38
3.09
-1.09
4.16
1.8
-6.23
-4.46
-6.69
Working Capital
28
23
30
33
39
43
35
33
39
51
40
30
23
22
LT Debt
3
2
12
27
33
35
40
27
25
24
28
28
26
24
Total Equity
94
105
110
129
146
166
181
175
175
187
180
167
156
153
Return on Invested Capital (%)
0.9
2.7
3.61
8.53
6.11
8.15
8.52
2.45
- -
4.49
1.72
- -
- -
- -
Return on Capital (%)
0.9
2.8
3.37
8.46
6.07
8.89
8.25
2.95
- -
4.41
2.36
- -
- -
- -
Return on Common Equity (%)
0.71
3.43
4.97
14.83
9.92
15.06
14
3.58
-1.39
5.97
2.22
-8.59
-6.78
-9.69

Capital Structure

PLN

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
64
144
114
LT Borrowings
12
11
10
LT Finance Leases
13
15
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
94
94
94
Market Capitalization
84
85
80

Working Capital

PLN

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
141
210
169
Cash, Cash Equivalents & STI
27
25
14
Accounts Receivable, Net
33
22
41
Inventories
67
148
114
Total Current Liabilities
118
187
147
Payables & Accruals
- -
- -
- -
ST Debt
64
144
114
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.95%
-2.15%
-6.36%
Free Cash Flow
-7,402.36%
185.08%
1,230.87%
Net Income, GAAP
-102.39%
-247.2%
-26.13%
Sales/Revenue/Turnover
6.39%
4.06%
3.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
52
61
61
61
236
2025
72
67
52
53
244
2026
59
- -
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
-0.07
-0.05
0.01
-0.15
2025
0.01
-0.01
-0.05
-0.06
-0.11
2026
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Wojciech Faszczewski
Full Time Employees
342
Sector
Consumer non-durables
Industry
Food: major diversified
Address
Poznanska Street 121 Lomza PD Poland 18-402
IPO Date
May 22, 1997
Website
pepees.pl
Business
Pepees S.A. operates extensively in the potato processing sector, serving both Polish and international markets. The company provides a range of essential potato-derived products, including various forms of potato starch, which finds applications across the food, pharmaceutical, textile, paper, and chemical industries. Additionally, it manufactures maltodextrin, a versatile ingredient critical for producing infant nutrition items, energy beverages, medical formulations, frozen meals, confectionery, and meat products. The company is also recognized as the sole domestic producer of crystalline glucose in Poland, a product utilized widely within the pharmaceutical, food, and chemical industries, as well as for direct consumption as a sweetener. Its offerings further extend to anhydrous glucose, formulated to pharmaceutical standards for drug and supplement creation, alongside glucose syrups primarily for confectionery use. A significant byproduct, feedstuff potato protein, serves as a valuable component in animal feed formulations. Headquartered in Łomża, Poland, Pepees S.A. holds the position of the largest starch potato processing facility in the country. The company is strategically pursuing modernization initiatives to increase production capacity and introduce novel products, enhancing its competitive standing. Recent developments include plans to launch a new starch modifier production line in early 2025, aimed at expanding into new food and pharmaceutical market segments and boosting revenues.